查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604758

自体细胞治疗市场：按来源、适应症和最终用户划分 - 2025-2030 年全球预测

Autologous Cell Therapies Market by Source (Bone Marrow, Chondrocytes, Epidermis), Indication (Autoimmune Disorders, Cancer, Cardiovascular Disorders), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

自体细胞治疗市场2023年估值为81.1亿美元，预计2024年将达到92.4亿美元，复合年增长率为14.52%，到2030年将达到209.6亿美元。

自体细胞疗法涉及使用患者自身的细胞来治疗或再生组织或器官，主要用于个人化医疗。对此类治疗的需求正在增加，因为它们有可能最大限度地减少免疫排斥并改善癌症、心血管疾病和神经退化性疾病等疾病的结果。其应用范围广泛，包括再生医学、癌症治疗、整形外科治疗等。最终用途多种多样，包括医院、诊所和研究机构，个人化和精准医疗日益成为优先事项。市场成长是由细胞研究的进步、慢性病盛行率的上升以及对细胞行为和操作的了解的加深所推动的，这些都为马苏的治疗开闢了新的途径。人工智慧和机器学习在预测性患者结果分析中的整合将进一步增加市场兴趣。儘管有这些机会，但诸如高成本、细胞处理的物流问题、监管障碍和缺乏标准化治疗通讯协定等挑战仍然是主要限制因素。对基因操纵和大规模生产的复杂性的道德担忧也阻碍了市场的无缝扩张。对于公司而言，投资于可扩展製造流程的研发和改进低温保存技术可以释放新的可能性。用于高效细胞处理和增强生物资讯工具的自动化和机器人技术创新可以提供竞争优势。促进生物技术公司、学术机构和医疗保健提供者之间的合作也可以促进从研究到临床应用的顺利过渡。自体细胞治疗市场的本质是动态且分散的，趋势表明对客製化和针对患者的解决方案的需求迅速增长。透过专注于这些创新和协作领域，公司可以克服挑战并利用这一变革时期生物技术领域的新兴机会。

主要市场统计
基准年[2023] 81.1亿美元
预计年份 [2024] 92.4亿美元
预测年份 [2030] 209.6亿美元
复合年增长率（%） 14.52%

市场动态：揭示快速发展的自体细胞治疗市场的关键市场洞察

自体细胞治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界各地慢性病的增加
    • 越来越重视新用途的药物开发
    • 随着医疗基础设施的改善，对个人化药物的需求不断增加
  • 市场限制因素
    • 自体细胞疗法相关的高成本
  • 市场机会
    • 自体细胞疗法生产分散化的技术进步
    • 政府增加细胞研究的投资
  • 市场挑战
    • 交货时间长和保存期限有限的问题

波特五力：驾驭自体细胞治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解自体细胞治疗市场的外在影响

外部宏观环境因素在塑造自体细胞治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解自体细胞治疗市场的竞争状况

自体细胞治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵自体细胞治疗市场供应商绩效评估

FPNV定位矩阵是评估自体细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了自体细胞治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，自体细胞治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地慢性病的发生率正在上升
      • 扩大对新应用药物开发的关注
      • 随着医疗基础设施的改善，对个人化医疗的需求不断增加。
    • 抑制因素
      • 自体细胞疗法相关的高成本
    • 机会
      • 自体细胞疗法製造分散化的技术进步
      • 政府增加细胞研究的投资
    • 任务
      • 与处理时间长和保留期限有限相关的问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章自体细胞治疗市场：依来源分类

  • 骨髓
  • 软骨细胞
  • 表皮
  • 造血干细胞
  • 间质干细胞

第七章 自体细胞治疗市场（按适应症）

  • 自体免疫疾病
  • 癌症
  • 心血管疾病
  • 神经退化性疾病
  • 整形外科
  • 伤口癒合

第八章自体细胞治疗市场：依最终使用者分类

  • 学术研究机构
  • 门诊手术中心
  • 医院/诊所

第九章 美洲自体细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区自体细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲自体细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Abata Therapeutics
  • Achilles Therapeutics plc
  • Adaptimmune Therapeutics PLC
  • Adicet Bio Inc.
  • AIVITA Biomedical, Inc.
  • Aspen Neuroscienc Inc.
  • Bellicum Phamaceuticals, Inc.
  • BioLineRx Ltd.
  • BioSpace, Inc.
  • BrainStorm Cell Limited.
  • Bristol-Myers Squibb Company
  • Carisma Therapeutics Inc.
  • Catalent, Inc.
  • Cell Therapy Catapult Ltd.
  • Fate Therapeutics Inc.
  • GentiBio, Inc.
  • IASO BioTherapeutics
  • Kyverna Therapeutics, Inc.
  • NOVADIP Biosciences SA
  • Orchard Therapeutics Inc.
  • T-knife Therapeutics, Inc.
  • ThermoGenesis Holdings, Inc.
  • Triumvira Immunologics Inc.
  • Vita Therapeutics, Inc.
Product Code: MRR-69324464D299

The Autologous Cell Therapies Market was valued at USD 8.11 billion in 2023, expected to reach USD 9.24 billion in 2024, and is projected to grow at a CAGR of 14.52%, to USD 20.96 billion by 2030.

Autologous Cell Therapies involve using a patient's own cells for the treatment and regeneration of tissues and organs, primarily in personalized medicine. The necessity for these therapies grows from their potential to minimize immune rejection and improve treatment outcomes for conditions like cancer, cardiovascular disorders, and neurodegenerative diseases. Their application spans across regenerative medicine, cancer therapies, orthopedic treatments, and beyond. The end-use scope is significant across hospitals, clinics, and research institutes, where personalized and precision medicine is increasingly prioritized. Market growth is driven by advancements in cell-based research, escalating prevalence of chronic diseases, and an enhanced understanding of cell behavior and manipulation, which open up innovative pathways for treatment. The integration of AI and machine learning in predictive analytics for patient outcomes further propels market interest. Despite these opportunities, challenges such as high costs, logistical issues with cell processing, regulatory hurdles, and a lack of standardized treatment protocols pose significant limitations. Ethical concerns about genetic manipulation and complexities in large-scale production also deter seamless market expansion. For businesses, investing in R&D for scalable manufacturing processes and improving cryopreservation techniques can unlock new possibilities. Innovations in automation and robotics for efficient cell handling and augmentation of bioinformatics tools could offer competitive advantages. Encouraging collaborations between biotech firms, academic institutions, and healthcare providers can also facilitate smoother transitions from research to clinical applications. The nature of the autologous cell therapy market is dynamic and segmented, with trends indicating a surging demand for customization and patient-specific solutions. By focusing on these areas of innovation and collaboration, companies can better position themselves to navigate challenges and capitalize on the burgeoning opportunities within this transformative sector of biotechnology.

KEY MARKET STATISTICS
Base Year [2023] USD 8.11 billion
Estimated Year [2024] USD 9.24 billion
Forecast Year [2030] USD 20.96 billion
CAGR (%) 14.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autologous Cell Therapies Market

The Autologous Cell Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in incidences of chronic diseases worldwide
    • Expanding focus on drug development for new applications
    • Growing need for personalized medicines with improving healthcare infrastructure
  • Market Restraints
    • High cost associated with autologous cell therapy
  • Market Opportunities
    • Technological advancements for decentralizing manufacturing of autologous cell therapy
    • Rising government investments in cell-based research
  • Market Challenges
    • Problems associated with long turnaround time and limited shelf life

Porter's Five Forces: A Strategic Tool for Navigating the Autologous Cell Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autologous Cell Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autologous Cell Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autologous Cell Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autologous Cell Therapies Market

A detailed market share analysis in the Autologous Cell Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autologous Cell Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autologous Cell Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autologous Cell Therapies Market

A strategic analysis of the Autologous Cell Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autologous Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Abata Therapeutics, Achilles Therapeutics plc, Adaptimmune Therapeutics PLC, Adicet Bio Inc., AIVITA Biomedical, Inc., Aspen Neuroscienc Inc., Bellicum Phamaceuticals, Inc., BioLineRx Ltd., BioSpace, Inc., BrainStorm Cell Limited., Bristol-Myers Squibb Company, Carisma Therapeutics Inc., Catalent, Inc., Cell Therapy Catapult Ltd., Fate Therapeutics Inc., GentiBio, Inc., IASO BioTherapeutics, Kyverna Therapeutics, Inc., NOVADIP Biosciences S.A., Orchard Therapeutics Inc., T-knife Therapeutics, Inc., ThermoGenesis Holdings, Inc., Triumvira Immunologics Inc., and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Bone Marrow, Chondrocytes, Epidermis, Haematopoietic Stem Cells, and Mesenchymal Stem Cells.
  • Based on Indication, market is studied across Autoimmune Disorders, Cancer, Cardiovascular Disorders, Neurodegenerative Disorders, Orthopedics, and Wound Healing.
  • Based on End-User, market is studied across Academics & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in incidences of chronic diseases worldwide
      • 5.1.1.2. Expanding focus on drug development for new applications
      • 5.1.1.3. Growing need for personalized medicines with improving healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with autologous cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for decentralizing manufacturing of autologous cell therapy
      • 5.1.3.2. Rising government investments in cell-based research
    • 5.1.4. Challenges
      • 5.1.4.1. Problems associated with long turnaround time and limited shelf life
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autologous Cell Therapies Market, by Source

  • 6.1. Introduction
  • 6.2. Bone Marrow
  • 6.3. Chondrocytes
  • 6.4. Epidermis
  • 6.5. Haematopoietic Stem Cells
  • 6.6. Mesenchymal Stem Cells

7. Autologous Cell Therapies Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Disorders
  • 7.3. Cancer
  • 7.4. Cardiovascular Disorders
  • 7.5. Neurodegenerative Disorders
  • 7.6. Orthopedics
  • 7.7. Wound Healing

8. Autologous Cell Therapies Market, by End-User

  • 8.1. Introduction
  • 8.2. Academics & Research Institutes
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Hospitals & Clinics

9. Americas Autologous Cell Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autologous Cell Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Cell Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abata Therapeutics
  • 2. Achilles Therapeutics plc
  • 3. Adaptimmune Therapeutics PLC
  • 4. Adicet Bio Inc.
  • 5. AIVITA Biomedical, Inc.
  • 6. Aspen Neuroscienc Inc.
  • 7. Bellicum Phamaceuticals, Inc.
  • 8. BioLineRx Ltd.
  • 9. BioSpace, Inc.
  • 10. BrainStorm Cell Limited.
  • 11. Bristol-Myers Squibb Company
  • 12. Carisma Therapeutics Inc.
  • 13. Catalent, Inc.
  • 14. Cell Therapy Catapult Ltd.
  • 15. Fate Therapeutics Inc.
  • 16. GentiBio, Inc.
  • 17. IASO BioTherapeutics
  • 18. Kyverna Therapeutics, Inc.
  • 19. NOVADIP Biosciences S.A.
  • 20. Orchard Therapeutics Inc.
  • 21. T-knife Therapeutics, Inc.
  • 22. ThermoGenesis Holdings, Inc.
  • 23. Triumvira Immunologics Inc.
  • 24. Vita Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOLOGOUS CELL THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOLOGOUS CELL THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CHONDROCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY EPIDERMIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HAEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023